Announcements Trials
Browse Landscape

Phase

Phase 1 12Phase 2 3Phase 1/2 3Phase 3 2Phase NA 1Phase EARLY_PHASE1 1Phase 4 1

Status

Recruiting 10Active not recruiting 5Completed 4Terminated 3Withdrawn 1Unknown 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 1Dermatologic 1CNS 1

Conditions

Prostatic Neoplasms 1Melanoma 1Glioma 1Diffuse Intrinsic Pontine Glioma 1

Interventions

pembrolizumab 75Carboplatin 61Cyclophosphamide 58Nivolumab 50Paclitaxel 47Gemcitabine 44Cisplatin 43Dexamethasone 41Radiotherapy 35Rituximab 32Capecitabine 31Docetaxel 29Bevacizumab 29fludarabine 27atezolizumab 26Cytarabine 26avelumab 24Trastuzumab 23Oxaliplatin 23Lenalidomide 23Cetuximab 23venetoclax 22Fluorouracil 22Azacitidine 22Temozolomide 21Ipilimumab 21130-nm albumin-bound paclitaxel 21fludarabine phosphate 20Filgrastim 20Bortezomib 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Terminated × ribociclib × Clear all
NCT02555189 2026-04-22

Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression

Thomas Jefferson University

Phase 1/2 Terminated
52 enrolled 31 charts
Genitourinary

Prostatic Neoplasms

NCT02607124 2020-11-05

A Phase I/II Study of Ribociclib,a CDK4/6 Inhibitor, Following Radiation Therapy

Children's Hospital Medical Center, Cincinnati

Phase 1/2 Terminated
11 enrolled 10 charts
CNS

Diffuse Intrinsic Pontine Glioma, Glioma

NCT01777776 2016-09-13

Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.

Array BioPharma

Phase 1/2 Terminated
28 enrolled 14 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡